Janus Henderson Group PLC Acquires 695,263 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Janus Henderson Group PLC lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,857,639 shares of the company's stock after buying an additional 695,263 shares during the quarter. Janus Henderson Group PLC owned 6.78% of IDEAYA Biosciences worth $150,606,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IDYA. Norges Bank acquired a new position in IDEAYA Biosciences in the fourth quarter valued at $13,385,000. FMR LLC boosted its holdings in IDEAYA Biosciences by 2.6% in the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after purchasing an additional 327,498 shares during the last quarter. Vanguard Group Inc. boosted its holdings in IDEAYA Biosciences by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after purchasing an additional 282,936 shares during the last quarter. WCM Investment Management LLC purchased a new position in IDEAYA Biosciences in the fourth quarter valued at about $6,030,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in IDEAYA Biosciences by 22.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock valued at $30,842,000 after purchasing an additional 220,000 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

IDYA traded up $0.51 during trading on Friday, reaching $17.82. 1,150,677 shares of the stock traded hands, compared to its average volume of 1,000,358. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -5.40 and a beta of 0.26. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The stock's 50-day simple moving average is $17.64 and its two-hundred day simple moving average is $22.18.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the business earned ($0.53) earnings per share. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reissued an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $54.27.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.